Opko Health, Inc.
OPK Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.63
KIRA · Stoqly’s AI analyst, in plain words
- Opko Health, Inc. had $607M of revenue in fiscal 2025, down 14.9% on the year before. Over five years, revenue changed −15.8% a year on average.
- Its operating margin was −19.3%, up 2.0 pts: of every 100 in sales, about −19 is left after running the business.
- Opko Health, Inc. lost $226M in fiscal 2025.
- Free cash flow was −$191M in fiscal 2025, −31.4% of revenue.
- Opko Health, Inc. returned $47.0M to shareholders in fiscal 2025. The diluted share count rose 8.2%.
- Opko Health, Inc. has $15.4M more cash than debt.
Market cap
$1.2B
P/E
—
Revenue
$607M
Net income
−$226M
Free cash flow
−$191M
Operating margin
−19.3%
Opko Health, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−14.9%
No. Sales fell 14.9% last year.
Does it make a profit?
−37.2%
No. It lost money last year.
Does profit turn into cash?
−31.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Opko Health, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- OPKO HEALTH, INC.
- CIK
- 0000944809
Opko Health, Inc. · OPK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.8B | $1.0B | $863M | $713M | $607M |
| Revenue growth | 23.6% | −43.4% | −14.0% | −17.4% | −14.9% |
| Gross margin | — | 28.7% | 36.8% | 30.6% | 33.9% |
| Operating margin | 1.1% | −22.5% | −18.2% | −21.3% | −19.3% |
| Net income | −$30.1M | −$328M | −$189M | −$53.2M | −$226M |
| Net margin | −1.7% | −32.7% | −21.9% | −7.5% | −37.2% |
| Diluted EPS | −$0.05 | −$0.46 | −$0.25 | −$0.08 | −$0.30 |
| Cash | |||||
| Cash from operations | $38.3M | −$95.2M | −$28.2M | −$183M | −$179M |
| Capital expenditure | $32.2M | $24.6M | $16.3M | $25.0M | $12.3M |
| Free cash flow | $6.2M | −$120M | −$44.5M | −$208M | −$191M |
| FCF margin | 0.3% | −11.9% | −5.2% | −29.2% | −31.4% |
| Share buybacks | — | $0.0M | $0.0M | $90.2M | $47.0M |
| Share count change | 1.2% | 11.0% | 4.5% | −7.7% | 8.2% |
| Debt and strength | |||||
| Cash and short-term investments | $135M | $153M | $95.9M | $427M | $364M |
| Debt incl. finance leases | $210M | $266M | $10.2M | $443M | $349M |
| Shareholders' equity | $1.7B | $1.6B | $1.4B | $1.4B | $1.3B |
| Net debt / EBITDA | 0.8x | — | — | — | — |
| Current ratio | 2.5x | 1.8x | 1.5x | 3.4x | 4.0x |
| Interest coverage | 1.0x | −18.8x | −11.6x | −3.2x | — |
| Returns and quality | |||||
| Return on capital | 0.8% | −10.7% | −9.6% | −8.7% | −7.4% |
| Return on equity | −1.8% | −20.2% | −12.8% | −3.9% | −17.1% |
| Return on tangible equity | −3.6% | −230.8% | −372.7% | −24.2% | −84.4% |
| Piotroski F-score | 5 | 1 | 4 | 3 | 4 |
| Altman Z'' | 1.8 | −0.2 | −1.1 | −0.4 | −0.8 |
Insiders bought, 12 months
$3.2M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Opko Health, Inc. · OPK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.63 a share, the company is worth $1.2B.
Source: SEC EDGAR XBRL filings (CIK 0000944809). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.